Carotegrast Methyl in Ulcerative Colitis

Summary

Carotegrast methyl, an oral α4-integrin inhibitor, was recently approved in Japan for the treatment of active ulcerative colitis (UC). However, real-world data regarding its efficacy and safety remain scarce. This study aimed to assess the clinical effectiveness and safety profile of carotegrast methyl in patients with active UC.

Timeline

Start

2022-06-01

Primary completion

2025-03-15

Completion

2025-03-15

Drugs

Indications